AutumnJacksonMcReeMD

Oncology • Chapel Hill, NC

Gastrointestinal Cancer

Associate Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine Director, Clinical Trials Program for GI Oncology

Join to view full profile

Dr. McRee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McRee's full profile

Already have an account?

Office
170 Manning Dr
Chapel Hill, NC 27514

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2008 - 2011
Vanderbilt University Medical CenterResidency, Internal Medicine, 2005 - 2008
McGovern Medical School at UTHealthClass of 2005

Certifications & Licensure

NC State Medical License 2011 - 2025
TN State Medical License 2007 - 2009
American Board of Internal Medicine Medical Oncology

Clinical Trials

BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer Start of enrollment: 2012 May 01
Completed
Phase 1
Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI Start of enrollment: 2012 Apr 01
Withdrawn
Phase 1
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer Start of enrollment: 2012 Nov 14
Active, not recruiting
Phase 2
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer Start of enrollment: 2012 Jan 01
Terminated
Phase 2
Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors Start of enrollment: 2013 Jun 01
Completed
Phase 1
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2014 Oct 01
Withdrawn
Phase 2
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Start of enrollment: 2014 Dec 01
Completed
Phase 1
Pembrolizumab Plus Y90 Radioembolization in HCC Subjects Start of enrollment: 2017 Mar 28
Active, not recruiting
Early Phase 1
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers Start of enrollment: 2017 Oct 06
Completed
Phase 2
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors Start of enrollment: 2018 Jan 30
Recruiting
Phase 1
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer Start of enrollment: 2018 Jun 05
Recruiting
Phase 1
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer Start of enrollment: 2019 Jun 12
Recruiting
Phase 2
LY3214996 +/- HCQ in Pancreatic Cancer Start of enrollment: 2020 May 27
Completed
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

118 citations
Erratum: Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles (Cell Reports (2017) 18(11) (2780–2794) (S221112471730214...
Vincenzo Cardinale, Eugenio Gaudio, Domenico Alvaro, Antonio Franchitto, Jean-Pierre A. Kocher
Cell Reports. 2017-06-27
806 citations
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro, Hyun Cheol Chung, Veena Shankaran, Ravit Geva, Daniel V.T. Catenacci
The Lancet. Oncology. 2016-06-01
61 citations
B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer.
Bhalchandra Mirlekar, Daniel Michaud, Samuel J. Lee, Nancy Porterfield Kren, Cameron Harris
Cancer Immunology Research. 2020-02-05

Press Mentions

Adjuvant Treatment Strategy Shows Promise in Pancreatic CancerMarch 13th, 2019